Paratek Pharmaceuticals Inc (PRTK) VP Adam Woodrow Sells 14,333 Shares

Paratek Pharmaceuticals Inc (NASDAQ:PRTK) VP Adam Woodrow sold 14,333 shares of the firm’s stock in a transaction that occurred on Tuesday, February 6th. The stock was sold at an average price of $13.87, for a total transaction of $198,798.71. Following the sale, the vice president now directly owns 62,367 shares in the company, valued at approximately $865,030.29. The sale was disclosed in a document filed with the SEC, which is available through the SEC website.

Shares of Paratek Pharmaceuticals Inc (NASDAQ PRTK) opened at $12.70 on Friday. Paratek Pharmaceuticals Inc has a one year low of $12.63 and a one year high of $29.00. The company has a debt-to-equity ratio of 0.49, a current ratio of 10.53 and a quick ratio of 10.53.

Paratek Pharmaceuticals (NASDAQ:PRTK) last released its quarterly earnings results on Wednesday, November 8th. The specialty pharmaceutical company reported ($0.77) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.93) by $0.16. Paratek Pharmaceuticals had a negative net margin of 1,236.38% and a negative return on equity of 100.84%. The firm had revenue of $0.01 million for the quarter. analysts expect that Paratek Pharmaceuticals Inc will post -3.32 EPS for the current year.

A number of equities research analysts have recently commented on the stock. Zacks Investment Research raised shares of Paratek Pharmaceuticals from a “hold” rating to a “buy” rating and set a $21.00 price objective on the stock in a research note on Wednesday, January 10th. ValuEngine cut shares of Paratek Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Friday, February 2nd. Robert W. Baird reissued a “buy” rating and issued a $40.00 price target on shares of Paratek Pharmaceuticals in a research note on Tuesday, October 24th. Guggenheim started coverage on shares of Paratek Pharmaceuticals in a research note on Tuesday, October 24th. They issued a “buy” rating and a $44.00 price target on the stock. Finally, Cantor Fitzgerald set a $50.00 price target on shares of Paratek Pharmaceuticals and gave the company a “buy” rating in a research note on Tuesday, October 17th. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. Paratek Pharmaceuticals has an average rating of “Buy” and a consensus target price of $39.63.

A number of institutional investors have recently added to or reduced their stakes in the stock. Cadence Capital Management LLC grew its stake in Paratek Pharmaceuticals by 101.2% in the 4th quarter. Cadence Capital Management LLC now owns 49,328 shares of the specialty pharmaceutical company’s stock valued at $883,000 after acquiring an additional 24,806 shares during the period. Moody Aldrich Partners LLC lifted its holdings in Paratek Pharmaceuticals by 26.3% in the 4th quarter. Moody Aldrich Partners LLC now owns 54,394 shares of the specialty pharmaceutical company’s stock valued at $974,000 after purchasing an additional 11,324 shares in the last quarter. Schwab Charles Investment Management Inc. lifted its holdings in Paratek Pharmaceuticals by 12.4% in the 4th quarter. Schwab Charles Investment Management Inc. now owns 92,366 shares of the specialty pharmaceutical company’s stock valued at $1,654,000 after purchasing an additional 10,202 shares in the last quarter. Iguana Healthcare Management LLC purchased a new position in Paratek Pharmaceuticals in the 3rd quarter valued at $879,000. Finally, Belpointe Asset Management LLC purchased a new position in Paratek Pharmaceuticals in the 3rd quarter valued at $228,000. 75.05% of the stock is currently owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION NOTICE: This piece was posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this piece on another domain, it was stolen and reposted in violation of international trademark & copyright laws. The correct version of this piece can be viewed at https://sportsperspectives.com/2018/02/09/paratek-pharmaceuticals-inc-prtk-vp-adam-woodrow-sells-14333-shares.html.

About Paratek Pharmaceuticals

Paratek Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics based upon tetracycline chemistry. Its product candidates are the antibacterials omadacycline and sarecycline. Omadacycline is an antibiotic being developed for use as an empiric monotherapy option for patients suffering from serious, community-acquired bacterial infections.

Insider Buying and Selling by Quarter for Paratek Pharmaceuticals (NASDAQ:PRTK)

Receive News & Ratings for Paratek Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paratek Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply